Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations. - Trial NCT05742802
Access comprehensive clinical trial information for NCT05742802 through Pure Global AI's free database. This Phase 3 trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 2544 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
AstraZeneca
Timeline & Enrollment
Phase 3
Mar 06, 2023
Aug 27, 2026
Primary Outcome
Time to first severe COPD exacerbation in former smokers.
Summary
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent
 for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3,
 extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with
 symptomatic COPD.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05742802
Non-Device Trial